Sahdeo Prasad

Sahdeo Prasad
Assistant Professor
Cytokine Research Laboratory
Department of Experimental Therapeutics
The University of Texas,
Anderson Cancer Center,
Houston TX 77054,
USA.
SPrasad@mdanderson.org

Dr. Sahdeo Prasad obtained his Ph.D. (Biotechnology), CSJM University, Kanpur, India in joint collaboration with Indian Institute of Toxicology Research (CSIR), Lucknow, India. During doctoral research program, he extensively worked on signal transduction pathways in both in vivo and in vitro tumor models. Before joining his PhD program, Dr. Prasad received National Eligibility Test (CSIR - UGC-NET), Graduate Aptitude Test in Engineering (GATE) and Indian Council of Medical Research Junior Research Fellowship award (ICMR-JRF) by Govt. of India. After PhD, he joined as Post - Doctoral Fellow in Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, USA. His expertise is in the area of molecular biology with particular reference to molecular mechanisms of signal transduction in tumor cells. Dr. Prasad has discovered a number of phytochemicals with chemo-preventive effects against a variety of cancers and their mechanism of action. The current research focuses of Dr. Prasad are on investigating the effects of chemo-preventive and chemotherapeutic agents among natural products that could suppress the activation of pro-inflammatory transcription factors NF-kB and STAT3. Besides these, Dr. Prasad’s work is also focused on the effect of natural compounds on death receptor pathways, bone loss and chemosensitization of tumor cells. He has numerous International publications, several book chapters and abstracts Indexed in International conferences. He is serving as an editor, guest editor, reviewer and editorial board member of various reputed journals. Dr. Prasad is also a member of number of scientific societies. He has also edited several books for Springer publishing company, Nova Science Publishers and Bentham science publishers.

Cancer, Inflammation, Natural compounds, Drug development, Anticancer agents